Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
51. |
ECCT/25/05/03 | Hibiscus 2 - Site 253 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Site 253 - International Cancer Institute (Uasin Gishu county) |
25-11-2025 |
View |
52. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
16-12-2025 |
View |
53. |
ECCT/25/05/01 | Sparkle Study Site 1403 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
18-12-2025 |
View |
54. |
ECCT/25/04/07 | Server migration Server Migration |
Principal Investigator(s) 1. Server Migration Server Migration Site(s) in Kenya Server Migration |
30-04-2025 |
View |
55. |
ECCT/25/04/04 | LIMIT A Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) |
Principal Investigator(s) 1. Anthony KIBUKA Gikonyo Site(s) in Kenya The Karen Hospital |
12-11-2025 |
View |
56. |
ECCT/25/04/03 | PRETERM AFRICA STUDY Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa |
Principal Investigator(s) 1. Nayirat Mohamed Site(s) in Kenya 1. Coast General Teaching and Referral Hospital (Mombasa county) |
10-03-2026 |
View |
57. |
ECCT/25/04/02 | PRETERM AFRICA STUDY Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa |
Principal Investigator(s) 1. Justus Simba Site(s) in Kenya 1. Mama Lucy Kibaki Hospital (Nairobi City county) |
10-03-2026 |
View |
58. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
07-10-2025 |
View |
59. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
16-09-2025 |
View |
60. |
ECCT/25/03/06 | Sparkle Study-Site 1404 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
26-11-2025 |
View |